Neal I. Muni
Chief Operating Officer chez Comera Life Sciences, Inc.
Fortune : - $ au 31/03/2024
Profil
Neal I.
Muni is currently the Director at CutisPharma Holdings, Inc. and the Chief Operating Officer at Comera Life Sciences, Inc. He was previously the Chief Executive Officer at Azurity Pharmaceuticals, Inc. from 2014 to 2020 and the Chief Operating Officer & Executive VP at Comera Life Sciences Holdings, Inc. He received his undergraduate degree from Brown University and his graduate and doctorate degrees from Tulane University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Neal I. Muni
| Sociétés | Poste | Début |
|---|---|---|
CutisPharma Holdings, Inc.
 CutisPharma Holdings, Inc. Pharmaceuticals: MajorHealth Technology CutisPharma Holdings, Inc. operates in the pharmaceuticals industry. The company is headquartered in Raleigh, NC. | Director/Board Member | - |
Comera Life Sciences, Inc.
 Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a private company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | Chief Operating Officer | - |
Anciens postes connus de Neal I. Muni
| Sociétés | Poste | Fin |
|---|---|---|
| COMERA LIFE SCIENCES HOLDINGS, INC. | Chief Operating Officer | 06/10/2023 |
Azurity Pharmaceuticals, Inc.
 Azurity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azurity Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on the needs of patients, especially children and the elderly, requiring customized, user-friendly drug formulations. The firm?s products include Epaned, Qbrelis, Xatmep and FIRVANQ oral solutions. The company was founded in 1998 and is headquartered in Woburn, MA. | Chief Executive Officer | 01/01/2020 |
Formation de Neal I. Muni
| Brown University | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| COMERA LIFE SCIENCES HOLDINGS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
CutisPharma Holdings, Inc.
CutisPharma Holdings, Inc. Pharmaceuticals: MajorHealth Technology CutisPharma Holdings, Inc. operates in the pharmaceuticals industry. The company is headquartered in Raleigh, NC. | Health Technology |
Azurity Pharmaceuticals, Inc.
Azurity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azurity Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on the needs of patients, especially children and the elderly, requiring customized, user-friendly drug formulations. The firm?s products include Epaned, Qbrelis, Xatmep and FIRVANQ oral solutions. The company was founded in 1998 and is headquartered in Woburn, MA. | Health Technology |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a private company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | Health Technology |
